Friedman H S, Lovell S, Rasheed K, Friedman A H
Duke University Medical Center, Durham, North Carolina 27710, USA.
Med Pediatr Oncol. 1998 Jul;31(1):16-8. doi: 10.1002/(sici)1096-911x(199807)31:1<16::aid-mpo3>3.0.co;2-2.
Exploration of the role of chemotherapy in the treatment of low grade glioma, including oligodendroglioma, has been limited to the pediatric population, reflecting the sensitivity of young patients to radiation-induced toxicity and a desire to avoid this intervention (7-12).
Nine adults with progressive oligodendroglioma were treated with carboplatin at a dose of 560 mg/m2 administered at 4 week intervals.
Eight patients have demonstrated stable disease as determined by serial MRI imaging at 2-3 month intervals with neither tumor regression nor growth noted. The ongoing duration of tumor control ranges between 6-22 months. Three patients have completed therapy with carboplatin and continue with stable dis-ease off chemotherapy. One patient progressed after 1 year of therapy with histologic confirmation of growth of well differentiated oligodendroglioma. Toxicity was limited to grade 3 thrombocytopenia in 3 patients and grade 3 neutropenia in 2 patients.
Carboplatin appears to be active in the treatment of adults with progressive oligodendroglioma. Further trials are warranted to more precisely define the role of carboplatin in the treatment of these tumors.
对化疗在包括少突胶质细胞瘤在内的低级别胶质瘤治疗中的作用的探索，一直局限于儿科人群，这反映了年轻患者对辐射诱导毒性的敏感性以及避免这种干预的愿望（7 - 12）。
9名患有进展性少突胶质细胞瘤的成年患者接受了卡铂治疗，剂量为560mg/m²，每4周给药一次。
通过每2 - 3个月进行一次的系列MRI成像确定，8名患者病情稳定，未观察到肿瘤缩小或生长。肿瘤控制的持续时间在6 - 22个月之间。3名患者已完成卡铂治疗，在停止化疗后病情继续稳定。1名患者在接受1年治疗后病情进展，组织学证实为高分化少突胶质细胞瘤生长。毒性仅限于3名患者出现3级血小板减少症和2名患者出现3级中性粒细胞减少症。
卡铂在治疗进展性少突胶质细胞瘤的成年患者中似乎有活性。有必要进行进一步试验以更精确地确定卡铂在这些肿瘤治疗中的作用。
